Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Authors :: Tesseur I
Lo AC
Roberfroid A
Dietvorst S
Van Broeck B
Borgers M
Gijsen H
Moechars D
Mercken M
Kemp J
D'Hooge R
De Strooper B
Source :: Science (New York, N.Y.) [Science] 2013 May 24; Vol. 340 (6135), pp. 924-e.
Publication Year :: 2013
Abstract: Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.

Subjects :: Animals
Male
Alzheimer Disease drug therapy
Alzheimer Disease metabolism
Amyloid beta-Peptides metabolism
Apolipoproteins E metabolism
Brain metabolism
Tetrahydronaphthalenes pharmacology
Tetrahydronaphthalenes therapeutic use

Full Text Access

Tools